Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
56 studies found for:    mdv3100 | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Condition: Breast Cancer
Interventions: Drug: enzalutamide;   Drug: anastrozole;   Drug: exemestane;   Drug: fulvestrant
2 Recruiting Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: exemestane;   Drug: Placebo (for enzalutamide)
3 Recruiting Enzalutamide in Patients With High-risk Prostate Cancer
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: enzalutamide
4 Recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Not yet recruiting A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Conditions: Prostate Cancer;   Castration-Resistant Prostate Cancer
Intervention: Drug: Enzalutamide
6 Recruiting An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Patients
Condition: Progressive Metastatic Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: Placebo
7 Recruiting Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer, Castrate-resistant
Interventions: Drug: Everolimus;   Drug: Enzalutamide
8 Recruiting RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)
Condition: Prostate Cancer
Interventions: Drug: Testosterone cypionate;   Drug: Testosterone Enanthate;   Drug: Abiraterone acetate;   Drug: Enzalutamide
9 Recruiting Molecular Features and Pathways in Predicting Resistance in Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Enzalutamide
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
10 Recruiting Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Condition: Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: Androgen Deprivation;   Radiation: Radiation Therapy
11 Recruiting Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: Enzalutamide;   Drug: LHRHa
12 Not yet recruiting Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Condition: Castration Resistant Metastatic Prostate Cancer
Interventions: Drug: Testosterone cypionate;   Drug: Enzalutamide;   Drug: Testosterone Enanthate
13 Recruiting Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Conditions: Nonmetastatic Castration-Resistant Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions: Drug: Enzalutamide;   Drug: Placebo
14 Recruiting Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Other: laboratory biomarker analysis
15 Recruiting A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Condition: Metastatic Castration-Resistant Prostate Cancer
Intervention: Drug: Enzalutamide
16 Recruiting Enzalutamide + External Beam Rt For Prostate
Condition: Intermediate Risk Prostate Cancer
Interventions: Drug: Enzalutamide;   Radiation: External Beam Radiation
17 Recruiting A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
Condition: Metastatic Castration- Resistant Prostate Cancer (mCRPC)
Intervention: Drug: Enzalutamide
18 Not yet recruiting Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Condition: Castration-resistant Prostate Cancer
Interventions: Drug: Crizotinib;   Drug: Enzalutamide
19 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
20 Recruiting A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Docetaxel;   Drug: Prednisolone;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years